Al Hammadi Company for Development and Investment

(A Saudi Joint Stock Company)

The Condensed Consolidated Interim
Financial Statements and Review Report
For the Three-Month and Nine-Month Periods Ended
30 September 2020



Al Azem, Al Sudairy, Al Shaikh & Partners CPA's & Consultants - Member Crowe Global

The Condensed Consolidated Interim Financial Statement and Review Report For The Three-month and Nine-month Periods Ended 30 September 2020

| Index | Page |
|---|------|
| Report on Review of Condensed Consolidated Interim Financial Statements | 1 |
| Condensed Consolidated Interim Statement of Profit or Loss | 2 |
| Condensed Consolidated Interim Statement of Comprehensive Income | 3 |
| Condensed Consolidated Interim Statement of Financial Position | 4 |
| Condensed Consolidated Interim Statement of Changes in Shareholders' Equity | / 5 |
| Condensed Consolidated Interim Statement of Cash Flows | 6 |
| Notes to Condensed Consolidated Interim Financial Statements | 7-17 |



Al Azem, Al Sudairy, Al Shaikh & Partners CPA's & Consultants
Member Crowe Global
C.R License No. 323/11/148
P.O. Box 10504 Riyadh 11443
Kingdom of Saudi Arabia
Telephone: +966 11 217 5000
Facsimile: +966 11 217 6000
Emall: ch@crowe.sa
www.crowe.com/sa

REPORT ON REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

The Shareholders Al Hammadi Company for Development and Investment (A Saudi Joint Stock Company)

Introduction

We have reviewed the accompanying condensed consolidated interim statement of financial position of Al Hammadi Company for Development and Investment (the "Company") and its subsidiaries (the "Group") as at 30 September 2020, and the related condensed consolidated interim statements of profit or loss, comprehensive income for the three and nine-month periods ended 30 September 2020, and the condensed consolidated interim statements of changes in shareholders' equity and cash flows for the nine-month period then ended, and a summary of significant accounting policies and other explanatory notes. Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with International Accounting Standard (34) "Interim Financial Reporting" that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed consolidated interim financial statements based on our review.

Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" that is endorsed in the Kingdom of Saudi Arabia. A review of condensed consolidated interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements are not prepared, in all material respects, in accordance with International Accounting Standard (34) "Interim Financial Reporting" that is endorsed in the Kingdom of Saudi Arabia.

العظم والسديري وال الشيخ وشركاؤهم محاسبون ومراجعون قانونيون نرخيص رقم المركبين المركبي المركبين المركبان المركبين المركبي المركبي المركبور المركب المركبي المركب المركبي المركبي المركب المركبي المركب المركب المركب المركبي المركب المواع المواع

Al Azem, Al Sudairy, Al Shaikh & Partners Certified Public Accountants

> Abdullah M. AlAzem License No. 335

22 Rabi Al-Awwal 1442 H (November 8, 2020) Riyadh, Kingdom of Saudi Arabia

Condensed Consolidated Interim Statement of Profit or Loss For the Three-month and Nine-Month Periods Ended 30 September 2020

| | Note | Three-month p | | Nine-month p 30 Sept | |
|---|------|---------------|---------------|-------------------------|---------------|
| | | 2020 | 2019 | 2020 | 2019 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) |
| | | SAR | SAR | SAR | SAR |
| Revenues | | 248,964,290 | 220,004,135 | 699,953,139 | 703,513,148 |
| Cost of revenues | | (166,428,841) | (157,786,456) | (460,129,702) | (504,609,864) |
| GROSS PROFIT | | 82,535,449 | 62,217,679 | 239,823,437 | 198,903,284 |
| General and Administrative expenses | | (31,517,519) | (25,297,607) | (84,799,997) | (88,666,781) |
| Selling and Marketing expenses | | (1,077,433) | (2,475,767) | (4,667,074) | (10,673,229) |
| Impairment losses on trade receivables | (6) | (5,612,232) | (2,594,295) | (19,036,058) | (9,572,704) |
| Impairment losses on property and equipment | (11) | - | | (4,994,185) | - |
| Other income | | 2,906,142 | 2,533,228 | 8,624,721 | 14,690,307 |
| OPERATING PROFIT | | 47,234,407 | 34,383,238 | 134,950,844 | 104,680,877 |
| Finance charges | | (5,818,467) | (9,464,857) | (19,987,581) | (28,080,950) |
| NET PROFIT BEFORE ZAKAT | | 41,415,940 | 24,918,381 | 114,963,263 | 76,599,927 |
| Zakat expense | | (4,850,000) | (3,750,000) | (14,350,000) | (11,250,000) |
| NET PROFIT FOR THE PERIOD | | 36,565,940 | 21,168,381 | 100,613,263 | 65,349,927 |
| Earnings per share: | | | | | |
| Basic and diluted profit for the period attributable to ordinary equity holders | (5) | 0.30 | 0.18 | 0.84 | 0.54 |

Condensed Consolidated Interim Statement of Comprehensive Income For the Three-month and Nine-month Periods Ended 30 2020

| | Three-month period ended 30 September | | 30 September | |
|--|---------------------------------------|---------------------|---------------------|---------------------|
| | 2020 (Unaudited) | 2019 (Unaudited) | 2020 (Unaudited) | 2019 (Unaudited) |
| | SAR | SAR | SAR | SAR |
| NET PROFIT FOR THE PERIOD | 36,565,940 | 21,168,381 | 100,613,263 | 65,349,927 |
| Other comprehensive (loss)/ income not to be reclassified to profit or loss in subsequent periods: | | | | |
| Re-measurement (loss)/ income on defined benefit plans | (1,702,125) | (2,460,851) | 1,080,471 | (3,830,695) |
| Total other comprehensive income / (loss) not to be reclassified to profit or loss in subsequent periods | (1,702,125) | (2,460,851) | 1,080,471 | (3,830,695) |
| TOTAL COMPREHENSIVE INCOME FOR THE PERIOD | 34,863,815 | 18,707,530 | 101,693,734 | 61,519,232 |
| | | A. | | |
| | | // | | |

Condensed Consolidated Interim Statement of Financial Position As at 30 September 2020

| | Notes | 30 September 2020 (Unaudited) SAR | 31 December 2019 (Audited) SAR |
|---|-------|--|---|
| ASSETS | | | |
| Non-current assets | | | |
| Property and equipment | | 1,674,723,051 | 1,738,721,572 |
| Right of use assets Goodwill | | 19,949,813 | 23,454,305 |
| | | 31,450,120 | 31,450,120 |
| Total non-current assets Current assets | | 1,726,122,984 | 1,793,625,997 |
| Inventories | | 60,361,046 | 49,018,443 |
| Trade receivables | (6) | 758,555,547 | 559,597,418 |
| Prepayments and other debit balances | (0) | 42,792,637 | 44,254,246 |
| Amounts due from related parties | | 4,805,980 | |
| Contracts assets | | 5,291,017 | 917,132 |
| Cash and cash equivalents | | 115,808,028 | 14,666,845 |
| Total current assets | | | 75,639,567 |
| | | 987,614,255 | 744,093,651 |
| TOTAL ASSETS | | 2,713,737,239 | 2,537,719,648 |
| SHAREHOLDERS' EQUITY AND LIABILITIES SHAREHOLDERS' EQUITY | | | |
| Share capital | (7) | 1,200,000,000 | 1,200,000,000 |
| Statutory reserve | , , | 51,138,685 | 51,138,685 |
| Retained earnings | | 416,685,884 | 314,992,150 |
| TOTAL SHAREHOLDRS' EQUITY | | 1,667,824,569 | 1,566,130,835 |
| LIABILITIES | | | |
| Non-current liabilities Loans | (10) | 455 226 057 | 100 551 000 |
| | (10) | 455,326,957 62,339,941 | 429,551,022 |
| Employees' termination benefits Lease liabilities | (8) | 10,018,196 | 59,871,135 13,149,588 |
| Government grants | (9) | 138,648,009 | |
| Total non-current liabilities | (9) | 666,333,103 | 144,358,206 646,929,951 |
| Current liabilities | | 000,333,103 | 040,929,931 |
| Trade payables | | 38,909,375 | 55,515,359 |
| Accrued expenses and other credit balances | | 62,134,425 | 69,962,426 |
| Amounts due to related parties | | _ | 18,900 |
| Loans | (10) | 128,732,761 | 144,640,065 |
| Government grants | (9) | 7,613,597 | 7,613,597 |
| Dividends payable | (-) | 287,735 | 287,735 |
| Zakat payable | | 14,349,981 | 16,619,782 |
| Lease liabilities | | 9,710,883 | 8,723,975 |
| Contracts liabilities | | 117,840,810 | 21,277,023 |
| Contracts natifities | | | |
| | | 379,579,567 | 324,658,862 |
| Total current liabilities TOTAL LIABILITIES | | 379,579,567 1,045,912,670 | 324,658,862 971,588,813 |

The accompanying notes (1) to (17) form an integral part of these condensed consolidated interim financial statements.

4

Al Hammadi Company for Development and Investment (A Saudi Joint Stock Company)

Condensed Consolidated Interim Statement of Changes in Shareholders' Equity For the Nine Month Period ended 30 September 2020

| | Share Capital | Statutory Reserve | Retained Earnings | Total Shareholders' |
|--------------------------------------|---------------|-------------------|-------------------|---------------------|
| | SAR | SAR | SAR | SAR |
| As at January 1, 2019 (Audited) | 1,200,000,000 | 41,838,718 | 236,759,335 | 1,478,598,053 |
| Net profit for the period | 1 | 1 | 65,349,927 | 65,349,927 |
| Other comprehensive loss | 1 | 1 | (3,830,695) | (3.830,695) |
| Total comprehensive income | 1 | 1 | 61,519,232 | 61,519,232 |
| Transfer to statutory reserve | 1 | 6,534,993 | (6,534,993) | 1 |
| As at September 30, 2019 (Unaudited) | 1,200,000,000 | 48,373,711 | 291,743,574 | 1,540,117,285 |
| As at January 1, 2020 (Audited) | 1,200,000,000 | 51,138,685 | 314,992,150 | 1,566,130,835 |
| Net profit for the period | 1 | 1 | 100,613,263 | 100,613,263 |
| Other comprehensive income | 1 | t | 1,080,471 | 1,080,471 |
| Total comprehensive income | ı | l | 101,693,734 | 101,693,734 |
| As at September 30, 2020 (Unaudited) | 1,200,000,000 | 51,138,685 | 416,685,884 | 1,667,824,569 |

Condensed Consolidated Interim Statement of Cash Flows For the Nine Month Period Ended 30 September 2020

| | Notes | 30 September 2020 | 30 September 2019 |
|--|-------|----------------------|----------------------|
| | | (Unaudited) SAR | (Unaudited) SAR |
| OPERATING ACTIVITIES | | | |
| Net profit before Zakat | | 114,963,263 | 76,599,927 |
| Adjustments to reconcile net profit before Zakat to net cash flow: | | | |
| Depreciation of property and equipment and right of use assets | | 76,714,669 | 76,641,552 |
| Impairment losses on trade receivables | (6) | 19,036,058 | 9,572,704 |
| Impairment losses on property and equipment | (11) | 4,994,185 | - |
| Loss on disposal of property and equipment | | 352,407 | - |
| Contract liability provided during the period | | 119,628,895 | 22,963,109 |
| Finance charges | | 19,987,581 | 28,080,950 |
| Government grants release | (9) | (5.710.197) | (5,710,198) |
| Current services cost of employees' termination benefits | (8) | 9,570,171 | 9,472,675 |
| Washing assisted adjustments | | 359,537,032 | 217,620,719 |
| Working capital adjustments: Trade receivables | | (217,994,187) | (188,181,494) |
| Inventories | | 9,375,828 | (3,016,610) |
| Contracts assets | | (11,342,603) | 6,898,979 |
| Net changes in related parties | | (3,907,748) | (1,714) |
| Prepayments and other debit balances | | 1,461,609 | 19,300,614 |
| Trade payables | | (17,145,994) | (3,957,191) |
| Accrued expenses and other credit balances | | (7.828,001) | 741,584 |
| Contracts liabilities | | (23,065,108) | (9,105,186) |
| Contracts nationals | | 89,090,828 | 40,299,701 |
| Employees' termination benefits paid | (8) | (7,420,354) | (12,224,432) |
| Zakat paid | (0) | (16,619,801) | (14,752,101) |
| Finance charges paid | | (8,783,530) | (16,481,989) |
| NET CASH RESULTED FROM (USED IN) OPERATING ACTIVITIES | | 56,267,143 | (3,158,821) |
| INVESTING ACTIVITIES | | (11 525 229) | (6.066.240) |
| Purchase of property and equipment | | (11,525,328) | (6,966,249) |
| NET CASH USED IN INVESTING ACTIVITIES | | (11,525,328) | (6,966,249) |
| FINANCING ACTIVITIES | | 72 172 205 | 107.055.606 |
| Proceeds from bank borrowings | | 73,173,205 | 107,055,696 |
| Repayment of bank borrowings | | (72,569,559) | (51,619,639) |
| Lease liabilities | | (5,177,000) | (5,477,000) |
| NET CASH (USED IN) RESULTED FROM FINANCING ACTIVITIES | | (4,573,354) | 49,959,057 |
| Net changes in cash and cash equivalents | | 40,168,461 | 39,833,987 |
| Cash and cash equivalents at the beginning of the period | | 75,639,567 | 43,863,138 |
| CASH AND CASH EQUIVALENTS AT SEPTEMBER, 30 Supplementary information for non-cash transactions | | 115,808,028 | 83,697,125 |
| Right of used assets additions | | 3,032,919 | |
| Accrued lease liabilities | | 540,010 | |
| Impact of adopted IFRS 16 | | _ | 32,189,513 |



Notes to Condensed Consolidated Interim Financial Statements For the Nine Month Period Ended 30 September 2020

1. Corporate information

Al Hammadi Company for Development and Investment (the "Company") was established as a limited liability Company under Commercial Registration No. 1010196714 issued on Safar 23, 1425H (corresponding to April 13, 2004) in Riyadh. On Ramadan 16, 1429H (corresponding to September 16, 2008), the Ministry of Commerce and Investment issued the resolution No. Q/316 to approve the Company's conversion to a closed joint stock Company. On Rajab 20, 1435H (corresponding to May 19, 2014) the Company obtained approval from the Capital Market Authority ("CMA") to issue 22.5 million shares in an initial public offering and the Company's shares were listed in Saudi Stock Exchange (Tadawul) on Ramadan 17, 1435H (corresponding to July 15, 2014).

The Company's registered address is Al-Olaya, P.O. Box 55004, Riyadh 11534, Saudi Arabia.

The main activities of the Company and its subsidiaries (the "Group") are wholesale and retail trading of medical equipment, pharmaceutical and cosmetic products, establishing, maintaining, managing and operating hospitals and medical centers, wholesale and retail trading of food and beverages, acquisition and rental of land for constructing buildings and investing them by means of selling or renting in favor of the Group, establishment or participation in different industrial projects, establishment of commercial centers, operating, and maintaining them in Saudi Arabia.

Details of subsidiary companies are as follows:

| | Country of | | Functional | Ownershi | p Interest |
|---------------------------|---------------|--------------------------|--------------|----------|------------|
| Name of Subsidiary | Incorporation | Business Activity | Currency | 2020 | 2019 |
| Medical Support Services | Saudi Arabia | Trading Company | Saudi Riyals | 100% | 100% |
| Company Limited | | | | | |
| Pharmaceutical Services | Saudi Arabia | Trading Company | Saudi Riyals | 100% | 100% |
| Company Limited | | | | | |
| Al Hammadi Company for | Saudi Arabia | Trading Company | Saudi Riyals | 100% | 100% |
| Hospitals Management, and | | | | | |
| Operations Company | | | | | |
| Limited | | | | | |
| Medical Industries | Saudi Arabia | Industries | Saudi Riyals | 100% | - |
| Company Limited | | Company | | | |
| | | | | | |

These consolidated financial statements include the accounts of the Group and following branches, which operate under separate commercial registrations:

| Branch Name | Commercial | City |
|---------------------------------|------------------|--------|
| | Registration No. | |
| Al Hammadi Hospital, Olaya | 1010263026 | Riyadh |
| Al Hammadi Hospital, Al-Suwaidi | 1010934227 | Riyadh |
| Al Hammadi Hospital, Al-Nuzha | 1010374270 | Riyadh |
| Maintenance & Operations | 1010374273 | Riyadh |
| Arabian Hospitality Ltd. | 1010610529 | Riyadh |
| | | |

Notes to Condensed Consolidated Interim Financial Statements - *continued* For the Nine Month Period Ended 30 September 2020

1. Corporate information - continued

In response to the spread of the Covid-19 virus in the world and the resulted disruptions to economic activities in the markets. The company's management has proactively assessed its impact on its operations to ensure the continuity of providing its services. Notwithstanding these challenges, the operations currently remain largely unaffected as the healthcare sector has been classified as an essential service by government and as result no restrictions have been placed by the government of kingdom of Saudi Arabia on company's operations or its supply chain. The company's management continues to monitor the financial and operational effects of the spread of the Covid-19 as well as the economic effects in general, and its measures have focused on managing the crisis in terms of operating efficiency and benefiting from the various government initiatives that aimed to support the health sector in the Kingdom. In addition, the company's management has taken measures to sustain the supply chain for medicines and medical and non-medical materials, which had the effect of increasing its stocks to secure operational needs in anticipation of any unexpected disruptions and meeting the unusual increase in demand for medicines and medical supplies. The company's management also has focused on the availability of sufficient cash balances to finance the operating requirements to ensure the continuation of its activity under these circumstances in which the outpatient visits has decreased during the closure period in the second quarter of the current year compared to the extraordinary increase of inpatient admissions resulted from the sudden increase of inpatients require continuous or intensive care needs which positively affected the revenues generated from health care services for

Despite the difficulty of determining the extent and duration of the impact of the spread of the Covid-19 epidemic, the company's management believes that it will not have a material impact on the company's ability to continue its activity. Management will also continue to monitor the situation closely, and will reflect any required impacts or changes in the financial reporting periods that pertain to it.

2. Basis of Preparation

2.1 Statement of Compliance

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 "Interim Financial Reporting" that is endorsed in Kingdom of Saudi Arabia and other standards and pronouncements that are issued by Saudi Organization of Certified Public Accountants (SOCPA) and should be read in conjunction with the Group's last annual financial statements as at and for the year ended 31 December 2019 ("last annual financial statements"). They do not include all of the information required for a complete set of IFRS financial statements, however; accounting policies and selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual financial statements.

2.2 Preparation of the Financial Statements

These condensed consolidated interim financial statements have been prepared on the historical cost basis except for the defined benefit obligation is recognised at the present value of future obligations using the Projected Unit Credit Method.

These condensed consolidated interim financial statements are presented in Saudi Riyal ("SAR"), which is the Group's functional and presentation currency. All amounts have been rounded to the nearest Saudi Riyal.

Notes to Condensed Consolidated Interim Financial Statements - *continued* For the Nine Month Period Ended 30 September 2020

2. Basis of Preparation - continued

2.3 Use of Judgments and Estimates

In preparing these condensed consolidated interim financial statements, management has made judgments and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements. However, as explained in Not 1 above, the group has reviewed the key sources of estimation uncertainties disclosed in the last annual consolidated financial statements against the backdrop of Covid-19 pandemic. Management believes that other than the expected credit losses arising on the financial assets and estimates of the variable consideration from which contractual liabilities arise as a result of the unusual increase in the degree of uncertainty, all other sources of estimation uncertainty remain similar to those disclosed in the annual consolidated financial statements. Management will continue to monitor the situation and any changes required will be reflected in future reporting periods.

3. Basis of Consolidation

These condensed consolidated interim financial statements comprising the condensed consolidated interim statement of financial position, condensed consolidated interim statement of profit or loss, condensed consolidated interim statement of comprehensive income, condensed consolidated interim statement of changes in shareholders' equity, condensed consolidated interim statement of cash flows and notes to the condensed consolidated interim financial statements of the Group include assets, liabilities and the results of the operations of the Company and its subsidiaries, as set out in note (1). Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are consolidated from the date on which control commences until the date on which control ceases. The Group accounts for the business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the acquisition is generally measured at fair value, as are the identified net assets acquired. The excess of the cost of acquisition over the fair value of the identifiable net assets acquired is recorded as goodwill in condensed consolidated interim statement of financial position. Intra-group balances and transactions, and any unrealised income and expenses arising from intra-group transactions, are eliminated. Accounting policies of subsidiaries are aligned, where necessary, to ensure consistency with the policies adopted by the Group. The Company and its subsidiaries have the same reporting periods.

4. Summary of Significant Accounting Policies

The accounting policies adopted in the preparation of the condensed consolidated interim financial statements are consistent with those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2019, except for the adoption of new standards:

New standards, amendments to standards and interpretations

There are no new standards issued, however, there are number of amendments to standards as follows:

- Amendments to standards which are effective from 1 January 2020 and has been explained in the Company's annual financial statements, but they do not have a material effect on the Company's condensed consolidated interim financial statements.
- Amendments to IFRS 16 Covid–19 "Related Rent Concessions" which are effective for the periods beginning on or after 1 June 2020. The amendment permits lessees, as a practical expedient, not to assess whether particular rent concessions occurring as a direct consequence of the Covid-19 pandemic are lease modifications and instead to account for those rent concessions as if they are not lease modifications. The amendment does not affect lessors. There is no material impact on the Company's condensed consolidated interim financial statements

Notes to Condensed Consolidated Interim Financial Statements - *continued* For the Nine Month Period Ended 30 September 2020

5. Earnings per share

Basic earnings per share (EPS) is calculated by dividing the profit for the period attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per share is the same as the regular or basic earnings per share as the Group does not have any convertible securities or diluted instruments to exercise.

The following table reflects the profit and share data used in the basic and diluted EPS computations:

| | 30 September | 30 September |
|--|--------------|--------------|
| | 2020 | 2019 |
| | SAR | SAR |
| Net profit for the period | 100,613,263 | 65,349,927 |
| Weighted average number of ordinary shares | 120,000,000 | 120,000,000 |
| Basic and diluted earnings per share | 0.84 | 0.54 |

6. Trade receivables

| 30 September | 31 December |
|--------------|---|
| 2020 | 2019 |
| (Unaudited) | (Audited) |
| SAR | SAR |
| 804,955,106 | 590,149,160 |
| (46,399,559) | (30,551,742) |
| 758,555,547 | 559,597,418 |
| | 2020 (Unaudited) SAR 804,955,106 (46,399,559) |

Unimpaired receivables are expected, on the basis of past experience, to be fully recoverable. It is not the practice of the Group to obtain collateral over receivables and they are therefore unsecured.

A majority of the receivables that are past due but not impaired are from government-linked entities which are inherently slow payers due to their long invoice acceptance and approval of payment procedures. Payments continue to be received from these customers and accordingly the risk of non-recoverability is considered to be low.

As at 30 September 2020, approximately 96.5% of the Group's trade receivables' balance was due from various governmental and insurance entities (31 December 2019: 96.2%).

The Group's credit terms require receivables to be repaid within 30-90 days depending on the type of customer, which is in line with healthcare industry. Due to short credit period offered to customers, a significant amount of trade receivables is neither past due nor impaired.

The summary for the movement of provision for impairment losses is as follows:

| | 30 September | 31 December |
|---|--------------|-------------|
| | 2020 | 2019 |
| | (Unaudited) | (Audited) |
| | SAR | SAR |
| 1 January | 30,551,742 | 21,531,756 |
| Additions during the period / year | 19,036,058 | 9,157,145 |
| Written off bad debits during the period / year | (3,188,241) | (137,159) |
| | 46,399,559 | 30,551,742 |

Notes to Condensed Consolidated Interim Financial Statements - *continued* For the Nine Month Period Ended 30 September 2020

7. Share capital

Share capital of the Company is 1,200 million SR consists of 120 million fully paid ordinary shares with a par value of SR 10 (31 December 2019: SR 1,200 million).

8. Employees' Termination Benefits

The following tables summarize the components of end of service benefits recognized in the condensed consolidated interim statement of profit or loss and amounts recognized in the condensed consolidated interim statement of comprehensive income and condensed consolidated interim statement of financial position:

a) Amount recognized in the condensed consolidated interim statement of financial position:

| | 30 September 2020 | 31 December 2019 |
|---|----------------------|------------------|
| | (Unaudited) SAR | (Audited) SAR |
| Present value of defined benefit obligation | 62,339,941 | 59,871,135 |

b) Benefit expense (recognized in consolidated statement of profit or loss):

| | 30 September | 30 September |
|-------------------------|---------------------------------------|--------------|
| | 2020 | 2019 |
| | SAR | SAR |
| | (Unaudited) | (Unaudited) |
| Current service cost | 9,570,171 | 9,472,675 |
| Special commission cost | 1,399,460 | 1,970,534 |
| Benefit expense | 10,969,631 | 11,443,209 |
| | · · · · · · · · · · · · · · · · · · · | |

Notes to Condensed Consolidated Interim Financial Statements - *continued* For the Nine Month Period Ended 30 September 2020

8. Employees' Termination Benefits - continued

| 0. | Employees Tellimation Denemes communica | | |
|------------|---|----------------------------|----------------------------|
| <i>c</i>) | Movement in the present value of defined benefit obligation: | | |
| | | 30 September 2020 | 31 December 2019 |
| | | (Unaudited) | (Audited) |
| | | SAR | SAR |
| Preser | at value of defined benefit obligation at beginning of the period \ | 59,871,135 | 56,204,516 |
| year | | 0 ==0 1=1 | 44.700.700 |
| | nt service cost | 9,570,171 | 11,529,708 |
| | al commission cost | 1,399,460 | 2,529,203 |
| | rial gain/ (loss) on defined benefit plan recognized in the consolidated tent of comprehensive income | (1,080,471) | 5,466,889 |
| Benef | its paid during the period \ year | (7,420,354) | (15,859,181) |
| Preser | at value of defined benefit obligation at end of the period \ year | 62,339,941 | 59,871,135 |
| d) | Principal actuarial assumptions: | | |
| | | 2020 | 2019 |
| | | SAR | SAR |
| | Discount rate | 3.1% | 4,5% |
| | Salary increase rate | 3% | 3% |
| | Retirement age | 60 years | 60 years |
| 9. | Government grants | | |
| | | 30 September 2020 | 31 December 2019 |
| | | (Unaudited) | (Audited) |
| | | SAR | SAR |
| | At 1 January | 151,971,803 | 159,585,400 |
| | Government grants released At the end of period \ year | (5,710,197) 146,261,606 | (7,613,597) 151,971,803 |
| | At the chu of periou (year | 140,201,000 | 131,771,003 |
| | | 30 September 2020 | 31 December 2019 |
| | | (Unaudited) | (Audited) |
| | | SAR | SAR |
| | Current | 7,613,597 | 7,613,597 |
| | Non-current | 138,648,009 146,261,606 | 144,358,206 151,971,803 |
| | | 140,401,000 | 131,7/1,003 |

Notes to Condensed Consolidated Interim Financial Statements - *continued* For the Nine Month Period Ended 30 September 2020

10. Loans

| | 30 September 2020 (Unaudited) SAR | 31 December 2019 (Audited) SAR |
|--------------------------------|--|---|
| Current portion: | | |
| Loans from Ministry of Finance | 34,678,480 | 18,714,240 |
| Loans from commercial banks | 94,054,281 | 125,925,825 |
| Total current portion | 128,732,761 | 144,640,065 |
| Non -current portion: | | |
| Loans from Ministry of Finance | 197,238,722 | 204,551,022 |
| Loans from commercial banks | 258,088,235 | 225,000,000 |
| Total non-current portion | 455,326,957 | 429,551,022 |
| Total | 584,059,718 | 574,191,087 |

10.1 Loans from ministry of finance

- On 11 September 2013, The Group obtained a loan from the Ministry of Finance to fund part of the construction of the new hospital in Al-Suwaidi area and the purchase of the indispensable medical and non-medical equipment. This loan qualifies to be considered as government grant because the Ministry of Finance represent a governmental body and provides the Group with a zero interest loan. The value of the loan is 149.1 million SR. The Group has utilized it in full as at 31 December 2017. This loan is in Saudi Riyals without any financing commissions and is collateralized by a mortgage of the project land and building. The loan is to be repaid over twenty equal annual installments after a grace period of five years of contract date.
- On 26 January 2015, the Group signed another financing agreement with the Ministry of Finance to fund the building of the housing compound related to Al-Suwaidi Hospital project. This loan qualifies to be considered as government grant because the Ministry of Finance represent a governmental body and provides the Group with a zero interest loan. The value of the loan is SR 27.5 million of which the Group has utilized it in full as at 31 December 2017. This loan is in Saudi Riyals without any financing commissions and is collateralized by a mortgage of the project land and building. The loan is to be repaid over twenty equal annual installments after a grace period of five years of contract date.
- On 20 July 2015, the Group signed a third financing agreement with the Ministry of Finance to fund part of the construction and furnishing costs of the hospital in Al-Nuzha area. This loan qualifies to be considered as government grant because the Ministry of Finance represent a governmental body and provides the Group with a zero interest loan. This loan amounted SR 197.6 million and the Group has utilized it in full as at 31 December 2018. This loan is in Saudi Riyals without any financing commissions and is collateralized by a mortgage of the project land and building. The loan is to be repaid over twenty equal annual installments after a grace period of five years of contract date.
- Loan installments due to the Ministry of Finance during the previous quarter amounting to SAR 17.3 million have been postponed for the next year, as part of the Ministry of Finance initiative to mitigate the economic impacts of the Covid-19 pandemic on the private sector.

Notes to Condensed Consolidated Interim Financial Statements - *continued* For the Nine Month Period Ended 30 September 2020

10. Loans - continued

10.2 Loans from commercial banks

In June 2020, the company modified the terms of a long-term facility agreement with a local bank by reducing the value of the installments to SAR 17.2 million for each quarterly installment that ends on June 30, 2025 instead of SAR 22.5 million, ending on June 30, 2023

The maturities of the loans are as follow:

| | 30 September 2020 SAR | 31 December 2019 SAR |
|------|-----------------------------|----------------------------|
| 2020 | 59,642,517 | 125,925,825 |
| 2021 | 51,617,647 | 90,000,000 |
| 2022 | 68,823,529 | 90,000,000 |
| 2023 | 68,823,529 | 45,000,000 |
| 2024 | 68,823,529 | - |
| 2025 | 34,411,765 | - |
| | 352,142,516 | 350,925,825 |

11. Impairment losses on property and equipment

The management has conducted a review of the recoverable value from capital work in progress that was put on hold since 2011, and the result reached that it is beyond potential use. Therefore, the asset has been impaired in full and impairment loss was recognized during the period amounted to SR 4,994,185.

Notes to Condensed Consolidated Interim Financial Statements - *continued* For the Nine Month Period Ended 30 September 2020

12. Segment Information

The Group's operations consist mainly of the medical services and pharmaceuticals products segment.

The following are selected financial information as at 30 September 2020 and 2019 by business segments:

- Medical Services segment: Fees for inpatient and outpatient services.
- Pharmaceuticals products segments.

| | Medical Services | | Pharmaceuticals Products | | Total | |
|---------------------|-------------------------|---------------|--------------------------|--------------------------------|---------------|---------------|
| 30 September | 2020 | 2019 | 2020 | 2019 | 2020 | 2019 |
| _ | SAR | SAR | SAR | SAR | SAR | SAR |
| | | | | | | |
| Revenue | 529,563,243 | 446,960,830 | 170,389,896 | 256,552,318 | 699,953,139 | 703,513,148 |
| Gross Profit | 190,326,774 | 117,304,448 | 49,496,663 | 81,598,836 | 239,823,437 | 198,903,284 |
| Depreciation | 74,772,014 | 75,180,916 | 1,942,655 | 1,460,636 | 76,714,669 | 76,641,552 |
| Net profit | 77,608,520 | 18,558,544 | 23,004,743 | 46,791,383 | 100,613,263 | 65,349,927 |
| | | | | | | |
| | Medical Services | | Pharmaceu | Pharmaceuticals Products Total | | otal |
| | 30 September | 21 D 2010 | 30 September | | 30 September | 21 D 2010 |
| | 2020 | 31 Dec 2019 | 2020 | 31 Dec 2019 | 2020 | 31 Dec 2019 |
| | SAR | SAR | SAR | SAR | SAR | SAR |
| | | | | | | |
| Total Assets | 2,462,974,043 | 2,267,968,222 | 250,763,196 | 269,751,426 | 2,713,737,239 | 2,537,719,648 |
| Total Liabilities | 982,202,556 | 944,214,036 | 63,710,114 | 27,374,777 | 1,045,912,670 | 971,588,813 |

13. Contingent liabilities

There are some legal cases in the normal course of business, and is currently pleading them, but the final outcome of such cases is not certain. Management will continue to monitor the situation and takes the necessary provision on conservative base even if it does not expect the outcome of these cases to be material on the condensed consolidated financial statements.

Notes to Condensed Consolidated Interim Financial Statements - *continued* For the Nine Month Period Ended 30 September 2020

14. Financial assets and financial liabilities

Financial instruments risk management objectives and policies

The main financial instruments carried on the Company's statement of financial position include cash and cash equivalents, accounts receivables and other debit balances, due from related parties, accounts payables, loans, due to related parties, accrued liabilities and other credit balances. The main purpose behind the Group's financial liabilities is to finance the operations and to provide guarantees to support the operations.

The Group's activities exposed it to various risks. These risks are: Market risk (which includes: Currency risk, fair value and cash flow interest rate risks and price risk), Credit risk and Liquidity risk. The Group's senior management oversees the management of these risks. The Group's senior management is supported by a financial risk committee that advises on financial risks and the appropriate financial risk governance framework for the Group. The financial risk committee provides assurance to the Group's senior management that the Group's financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with group policies and group risk appetite. The board of Directors reviews and agrees policies for managing each of these risks, which are summarized below.

Market Risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise three types of risk: interest rate risk, currency risk and other price risk such as equity price risk and commodity price risk.

Financial instruments affected by market risk include: loans, borrowings and deposits.

Currency Risk

It is the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. The Group's transactions are principally in Saudi Riyals and US Dollars. As the Saudi Riyal is pegged to US Dollar, the Group does not have significant exposure to currency risk. The Group has also some transactions in EURO which were not significant as at 30 September 2020 (31 December 2019).

Fair value and cash flow interest rate risks

The exposures to various risks associated with the effect of fluctuations in the prevailing interest rates on the Group's financial positions and cash flows. The Group monitors the commission rate fluctuations on a continuous basis and acts accordingly. The Group's commission rates principally relate to its borrowings and are subject to change on periodic basis.

Price Risk

Price risk is the risk that the value of a financial instrument will fluctuate as a result of changes in market prices, whether those changes are caused by factors specific to the individual instrument or its issuer or factors affecting all instruments traded in the market. The Group is currently not exposed to price risk as it has no investments in marketable securities.

Credit Risk

Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Group places its cash with banks that have sound credit ratings. Accounts receivables and due from related parties are carried net of provision for impairment losses.

Liquidity Risk

Liquidity risk is the risk that an enterprise will encounter difficulty in raising funds to meet commitments associated with financial instruments. Liquidity risk may result from an inability to sell a financial asset quickly at an amount close to its fair value. Liquidity risk is managed by monitoring on a regular basis that sufficient funds are available through committed credit facilities to meet any future commitments.

Notes to Condensed Consolidated Interim Financial Statements - *continued* For the Nine Month Period Ended 30 September 2020

15. Subsequent events

In the opinion of management, there have been no significant subsequent events since the period-end that require disclosure or adjustment in these condensed consolidated interim financial statements.

16. Comparative figures

Certain comparative figures have been reclassified to conform to the presentation in the current period figures as follows:

| | As previously | | |
|--|---------------|--------------------|-----------------|
| | reported | Re-classifications | As reclassified |
| General and Administrative expenses | (108,912,714) | 20,245,933 | (88,666,781) |
| Selling and marketing expenses | - | (10,673,229) | (10,673,229) |
| Impairment losses on Trade receivables | - | (9,572,704) | (9,572,704) |

17. Approval of the condensed consolidated interim financial statements

The consolidated financial statements have been approved by the board of directors on 22 Rabi al-Awwal 1442H (corresponding to November 8, 2020).